The Dublin-Boston score (DBS) [17,18] is a biomarker that captures the four-day change in IL-6:IL-10 and was shown to predict short-term clinical status in moderate-to-severely ill COVID-19 patients in the first week of hospitalization. This evidence concerns the gene IL6 and COVID-19.